Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study

Stefano Aliberti, Luis F. Reyes, Paola Faverio, Giovanni Sotgiu, Simone Dore, Alejandro H. Rodriguez, Nilam J. Soni, Marcos I. Restrepo, GLIMP investigators

Research output: Contribution to journalArticle

Abstract

Background Antibiotic resistance is a major global health problem and pathogens such as meticillin-resistant Staphylococcus aureus (MRSA) have become of particular concern in the management of lower respiratory tract infections. However, few data are available on the worldwide prevalence and risk factors for MRSA pneumonia. We aimed to determine the point prevalence of MRSA pneumonia and identify specific MRSA risk factors in community-dwelling patients hospitalised with pneumonia. Methods We did an international, multicentre study of community-dwelling, adult patients admitted to hospital with pneumonia who had microbiological tests taken within 24 h of presentation. We recruited investigators from 222 hospitals in 54 countries to gather point-prevalence data for all patients admitted with these characteristics during 4 days randomly selected during the months of March, April, May, and June in 2015. We assessed prevalence of MRSA pneumonia and associated risk factors through logistic regression analysis. Findings 3702 patients hospitalised with pneumonia were enrolled, with 3193 patients receiving microbiological tests within 24 h of admission, forming the patient population. 1173 (37%) had at least one pathogen isolated (culture-positive population). The overall prevalence of confirmed MRSA pneumonia was 3·0% (n=95), with differing prevalence between continents and countries. Three risk factors were independently associated with MRSA pneumonia: previous MRSA infection or colonisation (odds ratio 6·21, 95% CI 3·25–11·85), recurrent skin infections (2·87, 1·10–7·45), and severe pneumonia disease (2·39, 1·55–3·68). Interpretation This multicountry study shows low prevalence of MRSA pneumonia and specific MRSA risk factors among community-dwelling patients hospitalised with pneumonia. Funding None.

Original languageEnglish
Pages (from-to)1364-1376
Number of pages13
JournalThe Lancet Infectious Diseases
Volume16
Issue number12
DOIs
Publication statusPublished - Dec 1 2016

Fingerprint

Staphylococcal Pneumonia
Methicillin
Observational Studies
Cohort Studies
Pneumonia
Independent Living
Staphylococcus aureus
Patient Admission
Microbial Drug Resistance
Infection
Respiratory Tract Infections
Population
Multicenter Studies
Logistic Models
Odds Ratio
Regression Analysis
Research Personnel

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP) : an international, observational cohort study. / Aliberti, Stefano; Reyes, Luis F.; Faverio, Paola; Sotgiu, Giovanni; Dore, Simone; Rodriguez, Alejandro H.; Soni, Nilam J.; Restrepo, Marcos I.; GLIMP investigators.

In: The Lancet Infectious Diseases, Vol. 16, No. 12, 01.12.2016, p. 1364-1376.

Research output: Contribution to journalArticle

Aliberti, S, Reyes, LF, Faverio, P, Sotgiu, G, Dore, S, Rodriguez, AH, Soni, NJ, Restrepo, MI & GLIMP investigators 2016, 'Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study', The Lancet Infectious Diseases, vol. 16, no. 12, pp. 1364-1376. https://doi.org/10.1016/S1473-3099(16)30267-5
Aliberti, Stefano ; Reyes, Luis F. ; Faverio, Paola ; Sotgiu, Giovanni ; Dore, Simone ; Rodriguez, Alejandro H. ; Soni, Nilam J. ; Restrepo, Marcos I. ; GLIMP investigators. / Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP) : an international, observational cohort study. In: The Lancet Infectious Diseases. 2016 ; Vol. 16, No. 12. pp. 1364-1376.
@article{9603321650b643eabe1cced7f6ef5088,
title = "Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study",
abstract = "Background Antibiotic resistance is a major global health problem and pathogens such as meticillin-resistant Staphylococcus aureus (MRSA) have become of particular concern in the management of lower respiratory tract infections. However, few data are available on the worldwide prevalence and risk factors for MRSA pneumonia. We aimed to determine the point prevalence of MRSA pneumonia and identify specific MRSA risk factors in community-dwelling patients hospitalised with pneumonia. Methods We did an international, multicentre study of community-dwelling, adult patients admitted to hospital with pneumonia who had microbiological tests taken within 24 h of presentation. We recruited investigators from 222 hospitals in 54 countries to gather point-prevalence data for all patients admitted with these characteristics during 4 days randomly selected during the months of March, April, May, and June in 2015. We assessed prevalence of MRSA pneumonia and associated risk factors through logistic regression analysis. Findings 3702 patients hospitalised with pneumonia were enrolled, with 3193 patients receiving microbiological tests within 24 h of admission, forming the patient population. 1173 (37{\%}) had at least one pathogen isolated (culture-positive population). The overall prevalence of confirmed MRSA pneumonia was 3·0{\%} (n=95), with differing prevalence between continents and countries. Three risk factors were independently associated with MRSA pneumonia: previous MRSA infection or colonisation (odds ratio 6·21, 95{\%} CI 3·25–11·85), recurrent skin infections (2·87, 1·10–7·45), and severe pneumonia disease (2·39, 1·55–3·68). Interpretation This multicountry study shows low prevalence of MRSA pneumonia and specific MRSA risk factors among community-dwelling patients hospitalised with pneumonia. Funding None.",
author = "Stefano Aliberti and Reyes, {Luis F.} and Paola Faverio and Giovanni Sotgiu and Simone Dore and Rodriguez, {Alejandro H.} and Soni, {Nilam J.} and Restrepo, {Marcos I.} and {GLIMP investigators}",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/S1473-3099(16)30267-5",
language = "English",
volume = "16",
pages = "1364--1376",
journal = "The Lancet Infectious Diseases",
issn = "1473-3099",
publisher = "Lancet Publishing Group",
number = "12",

}

TY - JOUR

T1 - Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP)

T2 - an international, observational cohort study

AU - Aliberti, Stefano

AU - Reyes, Luis F.

AU - Faverio, Paola

AU - Sotgiu, Giovanni

AU - Dore, Simone

AU - Rodriguez, Alejandro H.

AU - Soni, Nilam J.

AU - Restrepo, Marcos I.

AU - GLIMP investigators

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Background Antibiotic resistance is a major global health problem and pathogens such as meticillin-resistant Staphylococcus aureus (MRSA) have become of particular concern in the management of lower respiratory tract infections. However, few data are available on the worldwide prevalence and risk factors for MRSA pneumonia. We aimed to determine the point prevalence of MRSA pneumonia and identify specific MRSA risk factors in community-dwelling patients hospitalised with pneumonia. Methods We did an international, multicentre study of community-dwelling, adult patients admitted to hospital with pneumonia who had microbiological tests taken within 24 h of presentation. We recruited investigators from 222 hospitals in 54 countries to gather point-prevalence data for all patients admitted with these characteristics during 4 days randomly selected during the months of March, April, May, and June in 2015. We assessed prevalence of MRSA pneumonia and associated risk factors through logistic regression analysis. Findings 3702 patients hospitalised with pneumonia were enrolled, with 3193 patients receiving microbiological tests within 24 h of admission, forming the patient population. 1173 (37%) had at least one pathogen isolated (culture-positive population). The overall prevalence of confirmed MRSA pneumonia was 3·0% (n=95), with differing prevalence between continents and countries. Three risk factors were independently associated with MRSA pneumonia: previous MRSA infection or colonisation (odds ratio 6·21, 95% CI 3·25–11·85), recurrent skin infections (2·87, 1·10–7·45), and severe pneumonia disease (2·39, 1·55–3·68). Interpretation This multicountry study shows low prevalence of MRSA pneumonia and specific MRSA risk factors among community-dwelling patients hospitalised with pneumonia. Funding None.

AB - Background Antibiotic resistance is a major global health problem and pathogens such as meticillin-resistant Staphylococcus aureus (MRSA) have become of particular concern in the management of lower respiratory tract infections. However, few data are available on the worldwide prevalence and risk factors for MRSA pneumonia. We aimed to determine the point prevalence of MRSA pneumonia and identify specific MRSA risk factors in community-dwelling patients hospitalised with pneumonia. Methods We did an international, multicentre study of community-dwelling, adult patients admitted to hospital with pneumonia who had microbiological tests taken within 24 h of presentation. We recruited investigators from 222 hospitals in 54 countries to gather point-prevalence data for all patients admitted with these characteristics during 4 days randomly selected during the months of March, April, May, and June in 2015. We assessed prevalence of MRSA pneumonia and associated risk factors through logistic regression analysis. Findings 3702 patients hospitalised with pneumonia were enrolled, with 3193 patients receiving microbiological tests within 24 h of admission, forming the patient population. 1173 (37%) had at least one pathogen isolated (culture-positive population). The overall prevalence of confirmed MRSA pneumonia was 3·0% (n=95), with differing prevalence between continents and countries. Three risk factors were independently associated with MRSA pneumonia: previous MRSA infection or colonisation (odds ratio 6·21, 95% CI 3·25–11·85), recurrent skin infections (2·87, 1·10–7·45), and severe pneumonia disease (2·39, 1·55–3·68). Interpretation This multicountry study shows low prevalence of MRSA pneumonia and specific MRSA risk factors among community-dwelling patients hospitalised with pneumonia. Funding None.

UR - http://www.scopus.com/inward/record.url?scp=84994495968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994495968&partnerID=8YFLogxK

U2 - 10.1016/S1473-3099(16)30267-5

DO - 10.1016/S1473-3099(16)30267-5

M3 - Article

AN - SCOPUS:84994495968

VL - 16

SP - 1364

EP - 1376

JO - The Lancet Infectious Diseases

JF - The Lancet Infectious Diseases

SN - 1473-3099

IS - 12

ER -